FDA accepts BLA review for Blenrep combo in relapsed or refractory MM
FDA accepts for review a BLA for Blenrep in combination with bortezomib plus dexamethasone and pomalidomide plus dexamethasone in MM.
Multiple Myeloma
Multiple Myeloma
Real-world study finds this triplet therapy is an option for daratumumab-refractory myeloma
A study showed that the triplet therapy isatuximab, pomalidomide, and dexamethasone (IsaPd) is an option for daratumumab-refractory multiple myeloma (MM), though the “modest”
Leukemia
News
EC approves blinatumomab in Ph-negative CD19+ B-ALL in the consolidation phase
By: Phillip McLeod The European Commission (EC) has approved blinatumomab (Blincyto) as a consolidation therapy for adult patients newly diagnosed with Philadelphia chromosome-negative,
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
News
Video Interviews
Multiple myeloma updates with Dr. Lonial
In a video interview during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, Sagar Lonial, MD,
Leukemia
Myelodysplastic Syndromes
News
Is unrelated cord blood better than bone marrow in haploidentical transplantation?
Haploidentical transplantation combined with unrelated cord blood resulted in superior one-year disease-free survival compared with the same transplant using bone marrow in patients
Lymphoma
Indolent B-Cell Lymphomas
News
Liso-cel receives positive CHMP opinion in relapsed or refractory follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of lisocabtagene maraleucel (lise-cel) for
Leukemia
Chronic Lymphocytic Leukemia
Longer-term ALPINE results show ‘sustained PFS benefit’ with zanubrutinib for CLL/SLL
After a median follow-up of 42.5 months, zanubrutinib resulted in a sustained progression-free survival (PFS) benefit compared with ibrutinib, with responses deepening over
Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
FDA grants Orphan Drug Designation to CD5-targeted CAR-T cell therapy for T-cell lymphoma
The US Food and Drug Administration (FDA) granted Orphan Drug designation to MB-105, a CD5-targeted chimeric antigen receptor (CAR)-T cell therapy, for the
Leukemia
Acute Myeloid Leukemia
News
Bone marrow microenvironment boosts AML patients’ response to donor lymphocyte infusion
Differences in the bone marrow microenvironment may determine why some relapsed acute myeloid leukemia (AML) patients respond better to donor lymphocyte infusion (DLI)
Myeloproliferative Neoplasms
Primary Myelofibrosis
Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume